ProfileGDS5678 / 1426405_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 61% 63% 64% 57% 59% 60% 60% 59% 56% 60% 59% 56% 59% 57% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.6950161
GSM967853U87-EV human glioblastoma xenograft - Control 23.7644263
GSM967854U87-EV human glioblastoma xenograft - Control 33.8433464
GSM967855U87-EV human glioblastoma xenograft - Control 43.404557
GSM967856U87-EV human glioblastoma xenograft - Control 53.4968559
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.6659860
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.6551160
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.5377959
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.4072656
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.5543160
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.5631459
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.3942556
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.5696959
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.4337357